Kyn Therapeutics

Ikena Oncology

Biotech

Ikena bags $120M to advance growing pipeline of cancer drugs

The round comes as Ikena prepares to add a TEAD inhibitor to its roster of clinical programs and advances a preclinical a first-in-class KRAS asset.

Nick Paul Taylor Jan 5, 2021 8:00am

celgene

Celgene strikes Obsidian deal to boost CAR-T options

Jan 18, 2019 8:50am

Mark Manfredi

I-O specialist Kyn comes out of stealth mode

Dec 14, 2017 8:55am